Tricarboxylic Acids

isocitrate dehydrogenase (NADP(+)) 1 ; Homo sapiens







30 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34756979 Long-term effect of fulvic acid amendment on the anammox biofilm system at 15 ℃: performance, microbial community and metagenomics analysis. 2022 Jan 1
2 32669607 Skp2 dictates cell cycle-dependent metabolic oscillation between glycolysis and TCA cycle. 2021 Jan 1
3 34145795 Landscape of IDH1/2 mutations in Chinese patients with solid tumors: A pan-cancer analysis. 2021 Aug 2
4 30483760 The oncometabolite d‑2‑hydroxyglutarate induces angiogenic activity through the vascular endothelial growth factor receptor 2 signaling pathway. 2019 Feb 2
5 30596429 Integrated Metabolomics and Lipidomics Analyses Reveal Metabolic Reprogramming in Human Glioma with IDH1 Mutation. 2019 Mar 1 1
6 30958073 Emerging drug profile: Krebs cycle and cancer: IDH mutations and therapeutic implications. 2019 Nov 2
7 31086759 Baseballs, tennis balls, livestock farm manure, the IDH1 mutation, endothelial cell proliferation and hypoxic pseudopalisading (granulomatous) necrosis: Mycobacterium avium subspecies paratuberculosis and the epidemiology, cellular metabolism and histology of diffuse gliomas, including glioblastoma. 2019 Apr 1
8 31278288 Comprehensive Metabolomic Analysis of IDH1R132H Clinical Glioma Samples Reveals Suppression of β-oxidation Due to Carnitine Deficiency. 2019 Jul 5 1
9 31660152 Isocitrate dehydrogenase inhibitors in acute myeloid leukemia. 2019 4
10 29738972 Steroids from Ganoderma sinense as new natural inhibitors of cancer-associated mutant IDH1. 2018 Sep 2
11 29847930 Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective. 2018 Oct 25 1
12 30511933 Nuclear magnetic resonance metabolic fingerprint of bevacizumab in mutant IDH1 glioma cells. 2018 Nov 26 1
13 28498812 Structure based discovery of clomifene as a potent inhibitor of cancer-associated mutant IDH1. 2017 Jul 4 2
14 28711227 Oncogenic Activities of IDH1/2 Mutations: From Epigenetics to Cellular Signaling. 2017 Oct 2
15 27097804 A high-throughput analysis of the IDH1(R132H) protein expression in pituitary adenomas. 2016 Aug 1
16 27355333 Targeting isocitrate dehydrogenase (IDH) in cancer. 2016 May 4
17 27528759 Isocitrate dehydrogenase (IDH), succinate dehydrogenase (SDH), fumarate hydratase (FH): three players for one phenotype in cancer? 2016 Aug 15 2
18 27624942 The oncometabolite 2-hydroxyglutarate activates the mTOR signalling pathway. 2016 Sep 14 3
19 25576295 Genetic variants in genes of tricarboxylic acid cycle key enzymes are associated with prognosis of patients with non-small cell lung cancer. 2015 Feb 1
20 25956465 Metabolic consequences of oncogenic IDH mutations. 2015 Aug 2
21 25980580 Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. 2015 May 20 1
22 24755473 IDH1 mutations alter citric acid cycle metabolism and increase dependence on oxidative mitochondrial metabolism. 2014 Jun 15 1
23 25355558 Genetic variations in IDH gene as prognosis predictors in TACE-treated hepatocellular carcinoma patients. 2014 Nov 1
24 23232569 Mutations in the isocitrate dehydrogenase genes IDH1 and IDH2 in tumors. 2013 Jan 1
25 23795241 Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase. 2013 Jun 13 2
26 24077277 An R132H mutation in isocitrate dehydrogenase 1 enhances p21 expression and inhibits phosphorylation of retinoblastoma protein in glioma cells. 2013 1
27 24295421 IDH mutations in tumorigenesis and their potential role as novel therapeutic targets. 2013 Dec 1
28 22385606 Isocitrate dehydrogenase mutation hot spots in acute lymphoblastic leukemia and oral cancer. 2012 Mar 2
29 22837861 Metabolomic analysis of bone morphogenetic protein receptor type 2 mutations in human pulmonary endothelium reveals widespread metabolic reprogramming. 2012 Apr-Jun 1
30 21289278 Profiling the effects of isocitrate dehydrogenase 1 and 2 mutations on the cellular metabolome. 2011 Feb 22 2